Preview

Научно-практическая ревматология

Расширенный поиск

Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям

https://doi.org/10.14412/1995-4484-2017-600-609

Полный текст:

Аннотация

В 2016 г., по истечении 10 лет после публикации, впервые были обновлены международные рекомендации Европейской антиревматической лиги (EULAR) по лечению подагры. Заключительный вариант обновленных рекомендаций, включающий три базовых постулата и 11 позиций, оговаривающих принципы проведения симптоматической терапии острого приступа артрита и, что более важно, стратегии урат-снижающей терапии, направлен на возможность их практического использования; однако некоторые, не лишенные неоднозначных суждений, положения требуют обсуждения и пояснения, в том числе исходя из российских реалий.

 

Об авторе

М. С. Елисеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Список литературы

1. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707

2. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004;63:1172-6. doi: 10.1136/ard.2004.023697

3. Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350

4. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. doi: 10.1136/ard.2006.055269

5. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490-5.

6. doi: 10.1136/annrheumdis-2011-200801

7. Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78:456-9. doi: 10.1016/j.jbspin.2011.05.010

8. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826-30.

9. doi: 10.1136/annrheumdis-2012-201676

10. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015;67(4):588-92. doi: 10.1002/acr.22469

11. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431-46. doi: 10.1002/acr.21772

12. Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349-5. doi: 10.1097/RHU.0b013e3182314d40

13. Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71 (6):929-34. doi: 10.1136/annrheumdis-2011-200156

14. Елисеев МС, Барскова ВГ, Денисов ИС. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. 2015;87(5):10-5 [Eliseev MS, Barskova VG, Denisov IS. Dynamics of clinical manifestations of gout in men (data from a 7-year retrospective observation). Terapevticheskii Arkhiv. 2015;87(5):10-5 (In Russ.)].

15. Елисеев МС, Барскова ВГ. Диета при подагре. Доктор.Ру. 2011;(1):55-8 [Eliseev MS, Barskova VG. Diet for gout. Doktor.Ru. 2011;(1):55-8 (In Russ.)].

16. Елисеев МС, Желябина ОВ. Влияние продуктов растительного происхождения на уровень мочевой кислоты: обзор литературы. Терапия. 2017;(4):52-8 [Eliseev MS, Zhelyabina OV. The influence of vegetable products on the level of uric acid: a review of literature. Terapiya. 2017;(4):52-8 (In Russ.)].

17. Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J. 2015;45(2):189-94. doi: 10.1111/imj.12661

18. Jalal DI, Chonchol M, Chen W, et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61:134-46.

19. doi: 10.1053/j.ajkd.2012.07.021

20. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyper-uricemia in the US general population: NHANES 2007-2008. Am J Med. 2011;125:679-87.e1. doi: 10.1016/j.amjmed.2011.09.033

21. Кудаева ФМ, Гордеев АВ, Барскова ВГ. Скорость клубочковой фильтрации у больных подагрой и факторы, на нее влияющие. Современная ревматология. 2007;1(1):42-6 [Kudaeva FM, Gordeev AV, Barskova VG. Glomerular filtration rate in patients with gout and factors influencing the rate. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2007;1(1):42-46. (In Russ.)]. doi: 10.14412/1996-7012-2007-438

22. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-96.

23. doi: 10.1002/art.22014

24. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900. doi: 10.1161/CIRCULATIONAHA.107.703389

25. De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69:1162-4. doi: 10.1136/ard.2009.122770

26. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2:e000282. doi: 10.1136/bmjopen-2011-000282

27. Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177-82. doi: 10.1136/annrheumdis-2012-202421

28. Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2015;10:e0134088. doi: 10.1371/journal.pone.0134088

29. Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252

30. Елисеев МС, Денисов ИС, Маркелова ЕИ и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевтический архив. 2017;89(5):10-9 [Eliseev MS, Denisov IS, Markelova EI, et al. Independent risk factors for the development of severe cardiovascular complications in men with gout: the results of a 7-year prospective study. Terapevticheskii Arkhiv. 2017;89(5):10-9 (In Russ.)].

31. Haj Mouhamed D, Ezzaher A, Neffati F, et al. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prevent Med. 2011;16(5):307-12. doi: 10.1007/s12199-010-0198-2

32. Hanna BE, Hamed JM, Touhala LM. Serum uric acid in smokers. Oman Med J. 2008;23(4):269-74.

33. Gee Teng G, Pan A, Yuan JM, Koh WP. Cigarette smoking and risk of incident gout in the Singapore Chinese Health Study. Arthritis Care Res (Hoboken). 2016;68(8):1135-42. doi: 10.1002/acr.22821

34. Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford). 2015;54(1):91-5. doi: 10.1093/rheumatology/keu304

35. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-9. doi: 10.1016/j.semarthrit.2008.08.006

36. Saseen JJ. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012;51(11):2004-12. doi: 10.1093/rheumatology/kes183

37. Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014 May;40(2):193-206. doi: 10.1016/j.rdc.2014.01.003

38. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi: 10.1002/art.27327

39. Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164:464-71. doi: 10.7326/M14-2070

40. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis:

41. a double-blind, randomized equivalence trial. Lancet. 2008;371:1854-60. doi: 10.1016/S0140-6736(08)60799-0

42. Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49:670-7. doi: 10.1016/j.annemergmed.2006.11.014

43. Zhang YK, Yang H, Zhang JY, et al. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014;68(5):633-8. doi: 10.1111/ijcp.12359

44. Федорова АА, Барскова ВГ, Якунина ИА, Насонова ВА. Кратковременное применение применение глюкокортикоидов

45. у больных затяжным и хроническим подагрическим артритом. Часть III – частота развития нежелательных реакций. Научно-практическая ревматология. 2009;47(2):38-42 [Fedorova AA, Barskova VG, Yakunina IA, Nasonova VA. Short term administration of glucocorticoids in patients with protracted and chronic gout arthritis. Part III – frequency of adverse events. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(2):38-42 (In Russ.)]. doi: 10.14412/1995-4484-2009-457

46. Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010;11:2933-8. doi: 10.1517/14656566.2010.529432

47. Алекберова ЗС, Барскова ВГ. Колхицин в ревматолoгии – вчера и сегодня. Будет ли завтра? Современная ревматология. 2010;4(2):25-9 [Alekberova ZS, Barskova VG. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(2):25-9 (In Russ.)]. doi: 10.14412/1996-7012-2010-598

48. Sivera F, Wechalekar MD, Andres M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009993. doi: 10.1002/14651858.CD009993.pub2

49. Bardin T, So A, Alten R, et al. Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal AntiInflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT. Arthritis Rheum. 2012;64(10 Suppl):S811-2.

50. Елисеев МС, Желябина ОВ, Барскова ВГ, Насонов ЕЛ. Опыт применения ингибитора интерлейкина1р канакинумаба

51. у больного с хронической тофусной подагрой. Научно-практическая ревматология. 2014;52(1):99-101 [Eliseev MS, Zhelyabin OV, Barskova VG, Nasonov EL. Experience of administration of canakinumab, an interleukin 1inhibitor, in a patient with chronic tophacaceous gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):99-101 (In Russ.)]. doi: 10.14412/1995-4484-2014-99-101

52. Елисеев МС, Желябина ОВ, Мукагова МВ, Насонов ЕЛ. Клинический опыт применения блокатора интерлейкина 1кана-кинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22 [Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):16-22 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-16-22

53. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063

54. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb random-ized, placebocontrolled trial. Circulation. 2012;126(23):2739-48. doi: 10.1161/CIRCULATIONAHA.112.122556

55. Елисеев МС, Желябина ОВ, Маркелова ЕИ др. Оценка кардиоваскулярного риска при применении ингибитора интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология. 2016;10(1):7-14 [Eliseev MS, Zhelyabina OV, Markelova EI, et al. Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):7-14 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-7-14

56. Елисеева МЕ, Цурко ВВ, Воробьев ПА. Пожилой пациент

57. с подагрой, лечение у терапевта. Клиническая геронтология. 2015;21(5-6):3-9 [Eliseeva ME, Tsurko VV, Vorob'ev PA. An elderly patient with gout, treatment with a therapist. Klinicheskaya Gerontologiya. 2015;21(5-6):3-9 (In Russ.)].

58. Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585-91. doi: 10.1080/15257770802136032

59. Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase IIItrials. Clin Ther. 2010;32:2386-97. doi: 10.1016/j.clinthera.2011.01.008

60. Crittenden DB, Kimmel JN, Pike VC, et al. Colchicine and risk of acute cardiovascular (CV) events among gout patients: the New York Department of veterans affairs retrospective cohort study. Arthritis Rheum. 2014;66(11 Suppl.):S65.

61. Solomon DH, Liu CC, Kuo IH, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-9.

62. doi: 10.1136/annrheumdis-2015-207984

63. Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679-85. doi: 10.1016/j.jacc.2013.01.055

64. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low dose colchicine for secondary prevention of cardiovascular disease. JACC. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027

65. Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2017 May 9.

66. doi: 10.1080/14397595.2017.1318467. [Epub ahead of print].

67. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy:results of a phase II random-ized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:876-84. doi: 10.1002/art.33412

68. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, random-ized, placebo-controlled trial. Rheumatology (Oxford). 2013;52:1285-92. doi: 10.1093/rheumatology/ket114

69. Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 2012;64:1462-70. doi: 10.1002/acr.21690

70. Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.

71. J Rheumatol. 2014;41:1703-11. doi: 10.3899/jrheum.131226

72. Елисеев МС. Подагра. В кн.: Ревматология. Клинические российские рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 253-64 [Eliseev MS. Gout. In: Revmatologiya. Klinicheskie rossiiskie rekomendatsii [Rheumatology. Clinical Russian recommendations]. Moscow: GEOTAR-Media; 2017. P. 253-64].

73. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91

74. Насонова ВА, Елисеев МС, Барскова ВГ. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Современная ревматология. 2007;1(1):31-6 [Nasonova VA, Eliseev MS, Barskova VG. Impact of age on the frequency and magnitude of the signs of metabolic syndrome in patients with gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2007;1(1):31-6 (In Russ.)].

75. doi: 10.14412/1996-7012-2007-436

76. Барскова ВГ, Елисеев МС, Зилов АВ, Насонов ЕЛ. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа. Ожирение и метаболизм. 2007;(1):19-23 [Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. The effect of hyperglycemia and hyperinsulinemia on the level of uric acid and the course of arthritis in patients with gout with type 2 diabetes mellitus.. Ozhirenie i Metabolizm. 2007;(1):19-23 (In Russ.)].

77. Pillinger MH, Bangalore S, Klein AB, et al. Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. J Manag Care Spec Pharm. 2017;23(6):677-83. doi: 10.18553/jmcp.2017.23.6.677

78. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2):156-60. doi: 10.1097/BOR.0b013e3283432d35

79. Becker MA, Schumacher H Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. doi: 10.1056/NEJMoa050373

80. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-8. doi: 10.1002/art.24209

81. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188-94. doi: 10.1093/rheumatology/ken457

82. Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39:1450-7. doi: 10.3899/jrheum.111375

83. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE. 2012;7:e50046.

84. doi: 10.1371/journal.pone.0050046

85. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93. doi: 10.2215/CJN.01580210

86. Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014;25(2):316-20. doi: 10.4103/1319-2442.128520

87. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30:217-26.

88. doi: 10.1111/j.1755-5922.2011.00277.x

89. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15:435 42. doi: 10.1111/j.1751-7176.2012.00701.x

90. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406-13.

91. doi: 10.1093/ndt/gft378

92. Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. doi: 10.1186/s12882-015-0047-z

93. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015 Jul;74(7):1368-72. doi: 10.1136/annrheumdis-2014-205269

94. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161-7. doi: 10.1016/S0140-6736(10)60391-1

95. Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a longterm follow-up study. Int J Clin Prac. 2009;63(9):1327-33.

96. doi: 10.1111/j.1742-1241.2009.02118.x

97. Gaffo AL, Dalbeth N, Saag KG, et al. Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study [abstract]. Arthritis Rheum. 2016;68 Suppl 10.

98. Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82:141-3. doi: 10.1016/j.jbspin.2015.01.002

99. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57:1324-8. doi: 10.1002/art.23007

100. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-60. doi: 10.1002/art.10511

101. Елисеев МС, Мукагова МВ, Смирнов АН и др. Атипичная подагра: тофусное поражение позвоночника. Научно-практическая ревматология. 2013;51(5):586-9 [Eliseev MS, Mukagova MV, Smirnov AV, et al. Atypical gout: spinal tophaceous injury. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):586-9 (In Russ.)]. doi: 10.14412/1995-4484-2013-1553

102. Барскова ВГ, Елисеев МС. Больная хронической подагрой: комментарии к течению болезни. Современная ревматология. 2010;4(1):32-8 [Barskova VG, Eliseev MS. Patient with chronic gout: comments on the course of the disease. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(1):32-8 (In Russ.)]. doi: 10.14412/1996-7012-2010-584

103. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007;46:1372-4. doi: 10.1093/rheumatology/kem056a

104. Mironczuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2017;63(1):68-78. doi: 10.1016/j.advms.2017.05.005. [Epub ahead of print].

105. Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13:453-60. doi: 10.1016/S1474-4422(14)70054-7

106. Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69:1418-23. doi: 10.1212/01.wnl.0000277468.10236.f1

107. Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:344-8. doi: 10.1002/gps.1469

108. Du N, Xu D, Hou X, et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer's Disease Risk. Mol Neurobiol. 2016;53(4):2594-9. doi: 10.1007/s12035-015-9271-6

109. Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169:1064-9. doi: 10.1093/aje/kwp033

110. Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166:561-7.

111. doi: 10.1093/aje/kwm127

112. Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson's disease: A meta-analysis. PLoS One. 2017;12(3):e0173731. doi: 10.1371/journal.pone.0173731

113. Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014;261:1133-8. doi: 10.1007/s00415-014-7331-x

114. Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016 Mar;75(3):547-51.

115. doi: 10.1136/annrheumdis-2014-206917. Epub 2015 Mar 4.

116. Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One. 2014;9(4):e94084. doi: 10.1371/journal.pone.0094084. eCollection 2014.

117. Verhaaren BF, Vernooij MW, Dehghan A, et al. The relation of uric acid to brain atrophy and cognition: the Rotterdam Scan Study. Neuroepidemiology. 2013;41(1):29-34. doi: 10.1159/000346606

118. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11:R46. doi: 10.1186/ar2659

119. Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609-13. doi: 10.1136/ard.2007.076182

120. Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the «dirty dish» hypothesis. Arthritis Rheum. 2011;63:4002-6. doi: 10.1002/art.30649

121. Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis. 2013;72(5):638-45. doi: 10.1136/annrheumdis-2012-202301

122. Eliseev M, Zhelyabina O, Vladimirov S, et al. Ultrasonography signs of MSU urate deposition in patients with hyperuricemia and early diagnosis of gout. Ann Rheum Dis. 2016;75 Suppl 2:1183. doi: 10.1136/annrheumdis-2016-eular.4166

123. Reinders MK, Haagsma C, Jansen T, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7. doi: 10.1136/ard.2008.091462

124. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51-6. doi: 10.1136/ard.2007.083071

125. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi: 10.1186/ar2978

126. Li S, Yang H, Guo Y, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Scientific Reports. 2016;6: Article number 33082. doi: 10.1038/srep33082

127. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-36. doi: 10.1002/art.34488

128. Jutkowitz E, Alarid-Escudero F, Choi HK, et al. Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout. Ann Intern Med. 2014;16:617-26. doi: 10.7326/M14-0227

129. Ryu H, Song R, Kim H, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2013;53:211-6. doi: 10.1177/0091270012439715

130. Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheum. 2016;12:235-42. doi: 10.1038/nrrheum.2015.132

131. Ramasamy SN, Korb-Wells CS, Kannangara DR, et al.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36:953-80. doi: 10.1007/s40264-013-0084-0

132. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74:2157-64.

133. doi: 10.1136/annrheumdis-2014-205577

134. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-40. doi: 10.1007/s11926-009-0019-z

135. Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-8. doi: 10.1136/annrheumdis-2016-210872

136. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-21. doi: 10.1002/art.30119

137. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-50.

138. Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96:90-8. doi: 10.1159/000434633

139. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58:2882-91. doi: 10.1002/art.23810

140. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60. doi: 10.1186/ar4497

141. Елисеев МС, Барскова ВГ, Якунина ИА. Диагноз подагра –противопоказние к назначению диуретиков. Фарматека. 2003;(5):67-70 [Eliseev MS, Barskova VG, Yakunina IA. Diagnosis of gout – contraindications to the appointment of diuretics. Farmateka. 2003;(5):67-70 (In Russ.)].

142. Ranieri L, Contero C, Andres M. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Ann Rheum Dis. 2017;6 Suppl 2:372. doi: 10.1136/annrheumdis-2017-eular.3905

143. Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. doi: 10.1136/bmj.d8190

144. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63-70. doi: 10.1016/j.phrs.2015.09.012

145. Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904-13.

146. doi: 10.1053/j.ajkd.2008.01.014

147. Ogata N, Fujimori S, Oka Y, et al. Effects of three strong statins(atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29:321-4. doi: 10.1080/15257771003741323

148. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157:255-7. doi: 10.1016/j.ijcard.2012.01.092


Для цитирования:


Елисеев М.С. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-609. https://doi.org/10.14412/1995-4484-2017-600-609

For citation:


Eliseev M.S. UPDATED EULAR GUIDELINES FOR THE MANAGEMENT OF GOUT. COMMENTS ON CERTAIN ITEMS. Rheumatology Science and Practice. 2017;55(6):600-609. (In Russ.) https://doi.org/10.14412/1995-4484-2017-600-609

Просмотров: 856


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)